Achaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $1.69 Million

Wall Street brokerages predict that Achaogen, Inc. (NASDAQ:AKAO) will post $1.69 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Achaogen’s earnings, with the lowest sales estimate coming in at $1.00 million and the highest estimate coming in at $4.15 million. Achaogen posted sales of $16.05 million in the same quarter last year, which would indicate a negative year over year growth rate of 89.5%. The business is expected to announce its next quarterly earnings report on Monday, November 6th.

According to Zacks, analysts expect that Achaogen will report full year sales of $1.69 million for the current year, with estimates ranging from $8.70 million to $15.85 million. For the next fiscal year, analysts expect that the company will report sales of $16.02 million per share, with estimates ranging from $4.87 million to $25.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Achaogen.

Achaogen (NASDAQ:AKAO) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.18). The business had revenue of $1.30 million during the quarter, compared to analysts’ expectations of $2.69 million. Achaogen had a negative net margin of 281.88% and a negative return on equity of 86.24%. The company’s revenue for the quarter was down 85.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.87) EPS.

AKAO has been the topic of a number of recent analyst reports. HC Wainwright initiated coverage on Achaogen in a research note on Thursday, June 15th. They issued a “buy” rating and a $29.00 price objective on the stock. BidaskClub upgraded Achaogen from a “hold” rating to a “buy” rating in a research note on Saturday, July 8th. Zacks Investment Research lowered Achaogen from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Stifel Nicolaus reiterated a “buy” rating and issued a $30.00 price objective on shares of Achaogen in a research note on Friday, August 4th. Finally, Mizuho initiated coverage on Achaogen in a research note on Wednesday, September 6th. They issued a “buy” rating and a $28.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company. Achaogen has an average rating of “Buy” and a consensus price target of $27.78.

Shares of Achaogen (NASDAQ:AKAO) traded down 9.04% on Friday, reaching $13.88. The company had a trading volume of 1,655,804 shares. The company has a 50-day moving average price of $17.09 and a 200-day moving average price of $20.84. Achaogen has a 52-week low of $3.68 and a 52-week high of $27.79. The firm’s market capitalization is $586.19 million.

In related news, COO Blake Wise sold 3,576 shares of the business’s stock in a transaction dated Tuesday, September 26th. The stock was sold at an average price of $15.99, for a total transaction of $57,180.24. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 8.36% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Sigma Planning Corp increased its stake in Achaogen by 9.6% during the second quarter. Sigma Planning Corp now owns 9,450 shares of the biopharmaceutical company’s stock valued at $205,000 after acquiring an additional 825 shares during the period. Bank of Montreal Can increased its stake in Achaogen by 33.3% during the second quarter. Bank of Montreal Can now owns 10,000 shares of the biopharmaceutical company’s stock valued at $217,000 after acquiring an additional 2,500 shares during the period. First Midwest Bank Trust Division increased its stake in Achaogen by 17.9% during the second quarter. First Midwest Bank Trust Division now owns 20,388 shares of the biopharmaceutical company’s stock valued at $443,000 after acquiring an additional 3,095 shares during the period. Bank of New York Mellon Corp increased its stake in Achaogen by 2.8% during the first quarter. Bank of New York Mellon Corp now owns 113,783 shares of the biopharmaceutical company’s stock valued at $2,871,000 after acquiring an additional 3,150 shares during the period. Finally, Essex Investment Management Co. LLC increased its stake in Achaogen by 14.4% during the second quarter. Essex Investment Management Co. LLC now owns 26,330 shares of the biopharmaceutical company’s stock valued at $572,000 after acquiring an additional 3,319 shares during the period. Hedge funds and other institutional investors own 84.15% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://ledgergazette.com/2017/10/09/achaogen-inc-akao-expected-to-post-quarterly-sales-of-1-69-million.html.

Achaogen Company Profile

Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).

Get a free copy of the Zacks research report on Achao

According to Zacks, analysts expect that Achaogen will report full year sales of $1.69 million for the current year, with estimates ranging from $8.70 million to $15.85 million. For the next fiscal year, analysts expect that the company will report sales of $16.02 million per share, with estimates ranging from $4.87 million to $25.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Achaogen.

Achaogen (NASDAQ:AKAO) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.18). The business had revenue of $1.30 million during the quarter, compared to analysts’ expectations of $2.69 million. Achaogen had a negative net margin of 281.88% and a negative return on equity of 86.24%. The company’s revenue for the quarter was down 85.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.87) EPS.

AKAO has been the topic of a number of recent analyst reports. HC Wainwright initiated coverage on Achaogen in a research note on Thursday, June 15th. They issued a “buy” rating and a $29.00 price objective on the stock. BidaskClub upgraded Achaogen from a “hold” rating to a “buy” rating in a research note on Saturday, July 8th. Zacks Investment Research lowered Achaogen from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Stifel Nicolaus reiterated a “buy” rating and issued a $30.00 price objective on shares of Achaogen in a research note on Friday, August 4th. Finally, Mizuho initiated coverage on Achaogen in a research note on Wednesday, September 6th. They issued a “buy” rating and a $28.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company. Achaogen has an average rating of “Buy” and a consensus price target of $27.78.

Shares of Achaogen (NASDAQ:AKAO) traded down 9.04% on Friday, reaching $13.88. The company had a trading volume of 1,655,804 shares. The company has a 50-day moving average price of $17.09 and a 200-day moving average price of $20.84. Achaogen has a 52-week low of $3.68 and a 52-week high of $27.79. The firm’s market capitalization is $586.19 million.

In related news, COO Blake Wise sold 3,576 shares of the business’s stock in a transaction dated Tuesday, September 26th. The stock was sold at an average price of $15.99, for a total transaction of $57,180.24. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 8.36% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Sigma Planning Corp increased its stake in Achaogen by 9.6% during the second quarter. Sigma Planning Corp now owns 9,450 shares of the biopharmaceutical company’s stock valued at $205,000 after acquiring an additional 825 shares during the period. Bank of Montreal Can increased its stake in Achaogen by 33.3% during the second quarter. Bank of Montreal Can now owns 10,000 shares of the biopharmaceutical company’s stock valued at $217,000 after acquiring an additional 2,500 shares during the period. First Midwest Bank Trust Division increased its stake in Achaogen by 17.9% during the second quarter. First Midwest Bank Trust Division now owns 20,388 shares of the biopharmaceutical company’s stock valued at $443,000 after acquiring an additional 3,095 shares during the period. Bank of New York Mellon Corp increased its stake in Achaogen by 2.8% during the first quarter. Bank of New York Mellon Corp now owns 113,783 shares of the biopharmaceutical company’s stock valued at $2,871,000 after acquiring an additional 3,150 shares during the period. Finally, Essex Investment Management Co. LLC increased its stake in Achaogen by 14.4% during the second quarter. Essex Investment Management Co. LLC now owns 26,330 shares of the biopharmaceutical company’s stock valued at $572,000 after acquiring an additional 3,319 shares during the period. Hedge funds and other institutional investors own 84.15% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://ledgergazette.com/2017/10/09/achaogen-inc-akao-expected-to-post-quarterly-sales-of-1-69-million.html.

Achaogen Company Profile

Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).

Get a free copy of the Zacks research report on Achaogen (AKAO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply